BI-754091 plus afatinib
T1220
Phase 2 small_molecule completed
Quick answer
BI-754091 plus afatinib for Esophageal Squamous Cell Carcinoma (ESCC) is a Phase 2 program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- China SXT Pharmaceuticals
- Indication
- Esophageal Squamous Cell Carcinoma (ESCC)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed